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Prolactinomas are the most prevalent functional benign pituitary tumors due to a pituitary
micro- or macroadenoma. The majority of patients presents with infertility and gonadal
dysfunction. A dopamine agonist (DA) (bromocriptine or cabergoline) is the treatment of
choice that can normalize prolactin levels, reduce tumor size, and restore ovulation and
fertility. Cabergoline generally preferred over bromocriptine because of its higher efficacy
and tolerability. Managing prolactinomas during pregnancy may be challenging. During
pregnancy, the pituitary gland undergoes global hyperplasia due to a progressive increase
in serum estrogens level that may lead to increase of the tumor volume with potential
mass effect and visual loss. The risk of tumor enlargement may occur in 3% of those with
microadenomas, 32% in those with macroadenomas that were not previously operated
on, and 4.8% of those with macroadenomas with prior ablative treatment. Though both
drugs appear to be safe during pregnancy, the data on fetal exposure to DAs during
pregnancy have been reported with bromocriptine far exceeds that of cabergoline with
no association of increased risk of pregnancy loss and premature delivery. It is advisable
to stop the use of DAs immediately once pregnancy is confirmed, except in the case of
women with invasive macroprolactinomas or pressure symptoms. This review outlines the
therapeutic approach to prolactinoma during pregnancy, with emphasis on the safety of
available DA therapy.
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Introduction
Prolactinomas are adenomas arising from lactotroph cells in the pituitary gland that secrete
prolactin, and are considered the most frequently diagnosed functioning pituitary tumor type,
accounting for about 40% of all pituitary adenomas (1). Prolactin production and release ismediated
via tonic inhibition by dopamine secreted by the hypothalamus. The breast is the main target tissue
for prolactin, but prolactin receptors have been found in several tissues, including the liver, ovary,
testis, and prostate (2). The primary action of prolactin is the initiation andmaintenance of lactation,
but it can act as a growth factor, neurotransmitter, or immunoregulator via autocrine or paracrine
mechanisms (3).
Prolactinomas are one of the causes of hyperprolactinemia, a condition in which 90% are
intersellar adenomas and 10% are macroadenomas (10mm) (4). Prolactinomas occur with a
prevalence of 60–100 cases per million (1). It is more common in women, particularly during the
reproductive period. The highest incidence rate was found in women between 25 and 34 years of
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age: 23.9/100,000 person-years (4). In women, prolactinomas are
usuallymicroadenomas (<10mm) presenting with high-prolactin
levels, which leads to amenorrhea, galactorrhea, and infertil-
ity. Men with prolactinomas frequently present with symptoms
of mass effects, such as headache and visual loss, and some-
times hypogonadism and infertility. Bone loss may occur as a
long-term consequence of hyperprolactinemia in both men and
women.
Dopamine agonists (DAs) have been increasingly used as a
treatment of choice for prolactinomas as it normalizes prolactin
levels and leads to tumor shrinkage. Surgery currently being
reserved for resistance or intolerance to DA, while radiotherapy
used only in cases of surgical failure or resistance to DA.
During pregnancy, the pituitary gland undergoes global hyper-
plasia due to a progressive increase in serum estrogens level
that may lead to increase of the tumor volume with potential
mass effect and visual loss, which poses significant challenge to
endocrinologists.
Prolactinoma During Pregnancy
Tumor cells in patients with prolactinomas express estrogen
receptors; as a result of the increased estrogen level during preg-
nancy (5), there can be a substantial increase in the volume of
the prolactinoma, with a progressive increase in serum prolactin
due to lactotroph cell hyperplasia (6). The main concern is pos-
sible tumor enlargement during pregnancy. The risk of tumor
enlargement during pregnancy is found to depend on tumor size.
Data in the literature indicate that although tumor enlargement
is only 3% for microprolactinomas, it is as high as 32% for
macroprolactinomas that were not previously operated on (7).
A magnetic resonance imaging (MRI) should be done before
conception to document tumor size and to serve as a baseline
for comparison with MRIs done during pregnancy. Furthermore,
MRI is helpful in distinguishing between hemorrhage into a tumor
versus simple tumor enlargement during pregnancy (8).
Although prolactinomas have been found to be amenable to
medical treatment during pregnancy, especially with DAs such as
bromocriptine, not enough safety data are available to recommend
the routine use of these drugs during pregnancy. The endocrine
society clinical practice guidelines for the management and treat-
ment of prolactinomas recommend the discontinuation of DAs
shortly after confirmation of pregnancy, with the exception of
women with invasive macroprolactinomas (5).
Bromocriptine is an ergoline derivative, a dopamine D2 recep-
tor agonist with agonist and antagonistic properties on D1 recep-
tors. It is generally required tomultiple dosing throughout the day
because of its short half life (9–11). In women taking bromocrip-
tine during early pregnancy, the incidence of abortions, ectopic
pregnancies, or congenital malformations is no higher than that in
the general population (12). In a study of 2,587 pregnant women,
out of which 2,437 were to increase the risk of spontaneous
abortion, congenital abnormalities, or multiple pregnancies, and
did not affect post-natal development (13). In other studies,
among 6,329 patients treated with bromocriptine during early
pregnancy, the risk of spontaneous abortions was 9.9%, which was
not higher than that in the general population (10.9%) (7, 14).
Moreover, long-term follow-up to 9 years of children born from
mothers taking bromocriptine did not cause detrimental effects
on fetal outcomes in term of physical development as well as
no psychomotor developmental abnormality reported to 5.5 years
(1–20 years) follow-up (15).
Furthermore, optimal outcome was found with continuous use
of bromocriptine throughout pregnancy in around 100 cases (16).
Cabergoline is an ergoline derivative DA with higher affinity
and selectivity for D2 dopamine receptors. It has long duration of
action allowing administration once or twice weekly with better
tolerability and patient compliance (17–20). Moreover, pregnancy
rate is higher with cabergoline in infertile women with prolacti-
noma than with bromocriptine (21).
The same results have been reported in women who were
on cabergoline before and during pregnancy (22, 23). In one
report, over 800 such pregnancies have been described (24) (of
which approximately 350 were exposed during the first weeks
of pregnancy), with no significant difference in the frequency of
spontaneous abortion, premature delivery, multiple pregnancy, or
neonatal malformations (25, 26).
In retrospective study on 103 pregnancies in 90 women with
hyperprolactinemia and the follow-up of the 61 children, no sig-
nificant abnormalities related neither to cabergoline doses nor
to the time of exposure (27). Data of 12 years follow-up in the
children born from mother treated with cabergoline showed no
influence on their post-natal development such as physical prob-
lems or of psychomotor retardation (28). In consistent with pre-
vious studies, finding from meta-analysis showed no significant
increase in the risk of miscarriages or fetal malformation with DA
used (29).
Quinagolide is a non-ergot DA, with selective dopamine-2
receptor agonist and long-lasting prolactin lowering effect. It
generally taken once daily and has better tolerability and con-
venient dosing schedule than bromocriptine (13, 30, 31). It has
limited safety compared with bromocriptine. In a review of 176
pregnancies in which quinagolide was used (average of 37 days),
spontaneous abortion occurred in 14%, 1 had premature delivery,
and 1 had ectopic gestation (13). In another small study of nine
pregnancies, there were two cases treated with two quinagolide
and had no complications (31).
Over 200 pregnancies have been recorded in women taking
quinagolide, and no apparent adverse effects on pregnancy or fetal
development have been detected (32).
Hence, everywomanwith prolactinomas should bemade aware
of the natural history of prolactinomas and should discuss her
plans to conceive with her physician, in order to be carefully
evaluated prior to becoming pregnant.
The determination of the appropriate treatment option is an
individual choice depending mainly on tumor size. The proposed
therapeutic approach is shown in Figure 1 (33). The outcomes of
prolactinomas after pregnancy have been extensively discussed,
with variable results. A recent study showed a prolactin normal-
ization rate of more than 40% without medical treatment, for a
median follow-up of 22months after delivery and cessation of
lactation (34).
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FIGURE 1 | Approach to managing prolactinomas during pregnancy.
Managing Microprolactinomas During
Pregnancy
Microprolactinomas in non-pregnant women tend to follow a
benign course. The risk of significant asymptomatic tumor growth
during pregnancy is 4.5% (35), and that of symptomatic tumor
growth is <2% (36). The risk of the development of new neuro-
logical sequelae (headaches, optic nerve compression, etc.) ranges
from 1.6 to 5.5% (37). Prolactin tends to increase during preg-
nancy; therefore, it does not reliably reflect an increase in tumor
size and is not useful for clinical assessment.
In the context of the very low risk of microprolactinoma
enlargement during pregnancy, there is considerable evidence
supporting the discontinuation of DA treatment once preg-
nancy is confirmed. The patient should be told that the risk of
enlargement of the adenoma during pregnancy is very small,
and medical treatment will likely be effective if symptoms do
occur.
The patient should be advised to report for urgent assessment
in case of unusual symptoms such as severe headache or visual
disturbance, to rule out the possibility of tumor enlargement.
Serial prolactin determinations are not necessary due to the high
variability of prolactin during pregnancy (38).
The patient should undergo baseline formal visual field testing
at the time of diagnosis and should be followed clinically every
2–3months during pregnancy (33), but serial MRI examinations
or visual field testing during pregnancy is not required. However,
there is no data documenting harm to the fetus from either MRI
scans or gadolinium (8).
In case the patient becomes symptomatic with visual distur-
bance or progressive headaches, an MRI without gadolinium (not
a CT) should be performed to assess changes in tumor size (39).
If substantial tumor growth is evident, the DA bromocriptine
should be restarted immediately (36), because it is the first drug
of choice in these cases.
For women who remain symptom-free throughout pregnancy,
serum prolactin should be measured 2months after delivery or
cessation of nursing, and if it is similar to the pretreatment value,
the drug should be restarted (40). Similarly, for women wishing to
breastfeed, an MRI scan should be done to ensure the stability of
the tumor within 4–6weeks of delivery (37), as DAs will decrease
serum PRL levels, subsequently impairing lactation.
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Managing Macroprolactinomas During
Pregnancy
In women, macroprolactinomas occur less frequently thanmicro-
prolactinomas. In case of macroprolactinoma, symptomatic
tumor enlargement occurs in 20–30% of cases (41). It has been
reported that the risk of clinically significant tumor enlargement
falls from over 30 to <5%, if the patient is treated with radiation or
surgery before pregnancy (25).
Pregnant women with large tumors and those with extrasellar
extension who have stopped bromocriptine are at risk for tumor
growth, and formal visual field testing should be done in each
trimester. Just like in microprolactinomas, it is not necessary to
measure serum prolactin levels throughout pregnancy, because
levels do not uniformly increase during gestation and do not
correlate with tumor enlargement (8, 25). Furthermore, in these
cases, the treatment should be individualized, as data comparing
various management strategies are lacking.
The patient should be informed about the relatively higher risk
of tumor enlargement, the need for normalization of prolactin,
and the importance of treatment before conception.
In the case of intrasellar and small macroprolactinomas that
do not abut the optic chiasm, DAs should be discontinued when
pregnancy is confirmed.
The patient should be advised about the symptoms and the need
for urgent evaluation once they appear. Close clinical monitoring
should be undertaken with formal visual field testing during each
trimester. If the patient reports headache or a change in vision, an
MRI should be performed. If the MRI finding is consistent with
tumor enlargement, the woman should be retreated with a DA (5).
Bromocriptine is considered as the first drug of choice, and it
usually decreases the size of the adenoma and eliminates symp-
toms (42). Cabergoline may be considered if the adenoma does
not respond to bromocriptine (43).
If the enlarged tumor does not respond to cabergoline ther-
apy, alternatives include transsphenoidal surgery in the sec-
ond trimester, or delivery if the pregnancy is advanced enough
(16, 25, 41).
Patients with large macroprolactinomas and those with
extrasellar extension are strongly discouraged from conceiving
until definitive therapy is undertaken. Therapy with surgical
debulking may be considered prior to pregnancy, because surgery
or radiation has been shown to decrease the risks of symptomatic
tumor enlargement (25), but there is high risk of hypopituitarism
in these cases. However, debulking surgery is a less preferable
option, since medical therapy during pregnancy is probably less
harmful than surgery (41). Women with prolactinomas that are
resistant to DAs are usually infertile. Therefore, pregnancy is
unexpected in these cases, unless they undergo ovarian stimula-
tion with gonadotropins or GnRH. Moreover, pregnancy is not
recommended in women with drug resistant large macropro-
lactinomas and they should not conceive even if the tumor is
intrasellar, until the size is reduced by transsphenoidal surgery.
Surgery is an option in cases with no tumor reduction during
medical treatment with DA, or in those who developed tumor
growth in a previous pregnancy (44).
Impact of Pregnancy and Breastfeeding on
Prolactin Levels, Tumor Volume, and
Remission Rate
The current literature demonstrates that pregnancy induces
remission of hyperprolactinemia in two-thirds of women after
discontinuation of DA. In one study, pregnancy has been found
to induce remission in 76% of non-tumoral hyperprolactinemia
(NTHP), 70% in microprolactinomas, and 64% in macroprolacti-
nomas with higher recurrence rate among patients with macro-
prolactinomas and those with microprolactinomas with visible
tumor on MRI at the time of treatment withdrawal (45).
In recent study, complete remission was found in 100% with
NTHP, 66% of patients with microprolactinomas, and 70% with
macroprolactinomas (46). Underlying mechanisms are uncertain
but have generally been attributed to the autoinfarction of the
tumor (46).
On the other hand, there is no data to suggest breastfeeding is
associated with an increased prolactin production or risk of tumor
enlargement (28, 46). Thus, women could breastfeed normally and
restart DA after cessation of lactation.
Conclusion
Managing prolactinoma during pregnancy is challenging. Clinical
trials highlighting the outcomes of medical therapy versus other
therapies are scarce; therefore, the patient is treated on an indi-
vidual basis. The outcome of microadenoma is excellent, allowing
patients to safely discontinue DAs with close clinical monitoring;
on the other hand, macroadenoma needs to be managed before
conception, as the risk of tumor enlargement is relatively high.
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